WEST HAVEN — Local pharmaceutical firm NanoViricides is hot on the heels of the Ebola virus and the growing world public-health threat its reemergence is posing.
The company is currently progressing in development of novel drug treatments for the virus that may work in spite of mutations. It has some previous research into Ebola treatments under its belt already, but those were sidelined to finish development of its leading drug candidate, the anti-flu treatment Injectable FluCide, in 2013.
The company is currently in negotiations with regard to testing the eventual treatments and has the capacity to produce the drug for clinical trials at its Shelton manufacturing facility.
The World Health Organization reports a total 3,967 suspected Ebola cases and 2,105 deaths as of this September. The virus has no known cure.